asco@alo33:161461 JSONTXT

Background: The purpose of the study as to assess changes in some immune system parameters in patients ith locally advanced cancer of the upper ja. Methods: Parameters of cellular and humoral immunity of 50 patients 27 men, 54 percent and 23 omen, 46 percent ere determined before antitumor treatment. The disease as diagnosed in 80 percent of the cases in patients aged 40-69 years. Results: Comparative analysis of results of immune status examinations in cancer patients and healthy people shoed statistically significant decrease in T-lymphocyte content in cancer patients due to subpopulations of helpersinductors x421;D4+ 31.6 2.0 and 43.7 2.3, respectively and increase in suppressorcytotoxic subpopulations CD8+ 28.4 percent 1.6 and 22.0 percent 1.9 resulting in a significant reduction in immunoregulatory index x421;D4+x421;D8+ 1.14 percent 0.08 and 1.85 percent 0.08 hich reflected increased immunosuppression in cancer patients by the beginning of treatment. Significant increase in spontaneous proliferative activity of lymphocytes as registered in cancer patients 17.3 percent 0.4 compared to healthy people 15.6 percent 0.7 . Inhibition of functional activity of lymphocytes as detected by the response to their stimulation by concanavalin A healthy people 30.0 percent 1.2, cancer patients 21.2 percent 0.6 and lipopolysaccharide healthy people 44.2 percent 1.4, cancer patients 31.9 percent 1.5 . B-lymphocyte content in patients ith cancer of the upper ja as similar to that in healthy people 17.7 percent 0.5 and 17.8 percent 0.8 . Blood serum shoed normal contents of main immunoglobulin classes IgG 10.8 gL 0.79, Igx410; 1.85 gL 0.27, Igx41C; 1.03 gL 0.16 . Immune status parameters did not depend on histological structure of tumors. Conclusions: Thus, immune status parameters in patients ith locally advanced cancer of the upper ja before the treatment ere similar to the parameters in patients ith locally advanced cancer despite tumor localization or histological structure. Such studies allo predicting the changes in the immune status of patients and correct its abnormalities during the treatment.,J Clin Oncol 34, 2016 suppl; abstr e17562 ,Publication Only Head and Neck Cancer